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Background: Noninvasive preclinical imaging methodologies such as small animal positron emission tomography
(PET) allow the repeated measurement of the same subject which is generally assumed to reduce the variability of
the experimental outcome parameter and to produce more robust results. In this study, the variability of tracer
uptake in the rodent brain was assessed within and between subjects using the established radiopharmaceuticals
18F-FDG and 18F-fallypride. Moreover, experimental factors with potential impact on study outcome were elicited,
and the effect of their strict homogenization was assessed.
Methods: Brain standardized uptake values of rodents were compared between three PET scans of the same
animal and scans of different individuals. 18F-FDG ex vivo tissue sampling was performed under variation of the
following experimental parameters: gender, age, cage occupancy, anesthetic protocol, environmental temperature
during uptake phase, and tracer formulation.
Results: No significant difference of variability in 18F-FDG or 18F-fallypride brain or striatal uptake was identified
between scans of the same and scans of different animals (COV= 14 ± 7% vs. 21 ± 10% for 18F-FDG). 18F-FDG brain
uptake was robust regarding a variety of experimental parameters; only anesthetic protocols showed a significant
impact. In contrast to a heterogenization approach, homogenization of groups produced more false positive effects
in 18F-FDG organ distribution showing a false positive rate of 9% vs. 6%.
Conclusions: Repeated measurements of the same animal may not reduce data variability compared with
measurements on different animals. Controlled heterogenization of test groups with regard to experimental
parameters is advisable as it decreases the generation of false positive results and thus increases external validity of
study outcome.
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Small animal positron emission tomography (PET) is a
frequently used methodology to investigate rodent models
of healthy and diseased states. Preclinical PET has been
revolutionized with the development of dedicated small
animal PET scanners [1-3]. Noninvasive imaging methods
such as PET are considered to give more reliable results in* Correspondence: martic@collegium.ethz.ch
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reproduction in any medium, provided the origlongitudinal follow-up studies where animals can be used
as their own control compared with studies where test
and control animals are not identical [1,4]. Additionally,
strict homogenization of experimental parameters reduces
variability within test groups and is therefore believed to
increase reliability of animal experiments [5,6]. Neverthe-
less, recent investigations on mouse behavior revealed that
the rate of false positive outcome was significantly higher
under homogenized conditions compared with an ap-
proach investigating pseudo-heterogenized groups [7].
Homogenization proved to decrease the reproducibility of
results among test groups. It is therefore suggested tos is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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to increase external validity of results, i.e., the applicability
of a result to other conditions, populations, or species [7-
10]. On the other hand, only homogenization of test
groups guarantees the detection of environmental influ-
ences on experimental outcome [6].
In this study, two representatives of different PET
tracer categories were investigated as exemplary tracers.
The glucose analogue 18F-FDG is the most frequently
used PET tracer in the clinic and a ‘metabolic’ tracer.
Previous studies in the field of small animal PET have
shown that the following experimental parameters cru-
cially impact biodistribution of 18F-FDG: anesthetic
agents, carrier gas, fasting, ambient temperature, and in-
jection type [11-16]. The dopamine D2 receptor ligand
(S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-18F-fluoropro-
pyl)-2,3-dimethoxybenzamide, 18F-fallypride, is a repre-
sentative of a radioligand binding reversibly to a site on
a neurotransmitter receptor. 18F-fallypride shows excel-
lent binding properties (high affinity and selectivity) and
imaging characteristics for the visualization of the dopa-
mine D2 receptor subtype [17-19].
The main focus of the inevitable variability determin-
ation was on the brain for 18F-FDG and on the striatum in
the case of 18F-fallypride. To investigate variability of
tracer uptake, it was important to choose an organ, which
can guarantee a certain intrinsic stability. A detailed study
on 18F-FDG tumor uptake variability showed 15.4 ± 12.6%
variability between two scans performed with a 6-h delay
on the same day [20]. Even though 18F-FDG is mainly
used for tumor studies, our study focuses on the brain,
due to less expected intrinsic variability.
In the first part of this study, the inherent variability of
18F-FDG brain and 18F-fallypride striatum uptake within
and between individual animals was assessed in a test-re-
test setup using a highly standardized protocol. The
second part was focusing on the determination of ex-
perimental factors, which might essentially impact the
outcome of 18F-FDG and 18F-fallypride rodent studies.
Finally, in a third part, homogenization and heterogeni-
zation of protocols were compared in terms of gender
differences of 18F-FDG biodistribution for an experimen-
tal setting with varying age of test animals and cage oc-
cupancy. It was observed that animal age often varies
not within one experimental group, but often between
different individual experiments. Purposely introducing
variation to an experimental setup might well feasibly be
achieved with animals of different age. The same holds
for the parameter cage occupancy. The latter often varies
between as well as within experimental setups.
The aim of this study was the assessment of suitable
small animal PET imaging protocols leading to minimal
inevitable tracer uptake variability and therefore of an esti-
mation of minimally detectable effect sizes in preclinicalPET studies. Furthermore, it was an attempt to transpose
the findings in behavioral experiments regarding the het-
erogenization in experimental setup to a more presumably
robust field of animal experimentation, i.e., PET tracer tis-
sue distribution. The translation of preclinical results to
the clinical setting is often problematic, and it can be
assumed that this is the case in PET research as well.
Methods
Animal preparation
Healthy animals were purchased from Charles River,
Sulzfeld, Germany. The investigated strains were Naval
Marine Research Institute (NMRI) mice, C57Bl/6J mice,
and Sprague Dawley (Crl:CD(SD)) rats with gender, age,
and group size as listed in Table 1.
Animal care and experimental procedures were per-
formed in accordance with and approved by the Swiss
Federal Veterinary Office. Animals were kept in standard
cages (groups of 2 to 13 animals per cage) in a Scantai-
ner (Scanbur, Denmark) equipped with a filter cover.
Three types of cages were used for animal housing. Pairs
of mice were kept in type II cages (16 × 22 × 14 cm3
(width × length × height); Tecniplast, Hohenspeissenberg,
Germany). Medium groups of three to eight mice were
housed in type III cages (22 × 37 × 15 cm3). Groups of up
to 13 mice as well as all groups of rats were kept in type
IV cages (33 × 55 × 25 cm3). Ambient temperature was
set to 23°C, and air humidity was between 50% and 85%.
Free access to food (Alleinfuttermittel for rats and mice,
KLIBA NAFAG, Kaiseraugst, Switzerland), and water
was allowed throughout all experiments. A light to dark
cycle of 12 h (dark phase, 6 p.m. to 6 a.m.) was main-
tained throughout all studies. Animal monitoring and
cage changes were performed weekly by the experi-
menter or a professional animal caretaker. Experiments
were started between 7 and 9 a.m. involving always the
same two experimenters.
Radiotracer application
18F-FDG was obtained from the commercial 18F-FDG
production of the University Hospital Zurich in batches
of 1 to 2 GBq. The radiosynthesis of 18F-fallypride was
performed according to the protocol of Mukherjee et al.
[14]. The radioligand was produced in batches of 500 to
5,000 MBq, with activity concentrations of 500 to 2,000
MBq/mL and specific activities between 54 and 260
GBq/μmol at the end of synthesis. Radiotracer injection
into rats was performed using the VasofixWBraunüleW
(Braun AG, Melsungen, Germany) catheter. Tail vein
injections of approximately 15 MBq 18F-FDG in 300 μL
of physiological NaCl solution (Braun AG) were followed
by rinsing the catheter with 150 μL of physiological
NaCl solution. In mice, approximately 15 MBq 18F-FDG
in 100 μL of physiological NaCl solution were directly











Experiment Strain n FDG fallypride Control (6) 40 60 RT 33 Yes No M F 5 7 to 10 14 2 3 to 8 13
Test-retest study 1 SD rat 6 x x x x x x x
Test-retest study 2 SD rat 6 x x x x x x x
Test-retest NMRI 6 x x x x x x x
C57BL/6 J 7 x x x x x x x
Anesthetic impact SD rat 6 x x x x x x
SD rat 7 x x x x x x
SD rat 7 x x x x x x
Temperature/
EtOH impact
NMRI 8 x x x x x x x
NMRI 8 x x x x x x x
NMRI 8 x x x x x x x
NMRI 8 x x x x x x x
Homogenization/
heterogenization
NMRI 10 x x x x x x x
NMRI 10 x x x x x x x
NMRI 11 x x x x x x x
NMRI 11 x x x x x x x
NMRI 9 x x x x x x x
NMRI 8 x x x x x x x
NMRI 11 x x x x x x x
NMRI 12 x x x x x x x
x, Experimental parameters applied for each individual animal group; EtOH, ethanol; C57Bl/6J mice; NMRI, Naval Marine Research Institute mice; SD rat, Sprague-
Dawley rat.
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injected into mice via direct tail vein injection of 100 μL.
In order to keep the injected cold mass constant
over each test day, decreasing radioactive doses of
18F-fallypride were injected over each test day (between
18 and 2 MBq). Over all test days, the injected cold mass
of 18F-fallypride was between 20 to 130 ng correspond-
ing to 1.5 to 9.0 nmol/kg body weight.
Small animal PET imaging
All PET experiments were performed at the Animal Im-
aging Center (Center for Radiopharmaceutical Sciences,
ETH Zurich) using the dedicated 36-module eXplore
Vista-PET/CT tomograph (GE Healthcare, Waukesha,
WI, USA) with a maximum resolution of higher than 2
mm full width at half maximum and a field of view
(FOV) with an axial length of 48 mm and a diameter of
67 mm [21]. Animals underwent one bed position scans
with the brain in the center of the FOV.
PET protocol 1: anesthesia induction after tracer injection
Animals were restrained and injected 30 min (18F-FDG)
and 20 min (18F-fallypride) before scan start. The urinary
bladder was emptied by pressing the lower abdomen be-
fore induction of anesthesia 10 min before scan start,and animals were then fixed on the bed of the scanner.
Isoflurane was used as anesthetic agent of choice with
oxygen/air (50%/50%) as carrier gas. Data were acquired
from 30 to 60 min post injection (p.i.) for 18F-FDG emis-
sion scans and from 20 to 60 min p.i. for 18F-fallypride
emission scans (energy window 250 to 700 keV). Images
were reconstructed using a two-dimensional-ordered
subset expectation maximization algorithm (2 iterations,
16 subsets) with scatter and random correction; no at-
tenuation correction was performed. Voxel size of
reconstructed images was 0.3875 × 0.3875 × 0.775 mm3.PET protocol 2: anesthesia induction before tracer injection
Animals were anesthetized, and an injection catheter
(VasofixWBraunüleW (Braun AG), 22 G, 0.9 × 25 mm)
was placed in a lateral tail vein and rinsed with 100 μL
Heparin solution (Heparin-Na (Bichsel AG, Interlaken,
Switzerland), 25,000 I.E./5 mL) before animals were
positioned on the scanner bed. Tracer injection and PET
scan start were performed simultaneously. Data was
acquired from 0 to 60 min p.i. for 18F-FDG emission
scans in the list mode format (energy window 250 to
700 keV). Data were split into two time frames of 30
min each, and images were reconstructed as described
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30 min frame was further investigated.
Reconstructed images were inspected in coronal, sagit-
tal, and transverse planes throughout the reconstructed
volume. Region of interest (ROI) analysis was performed
with the biomedical image quantification software PMOD
(Pmod Technologies Ltd, Adliswil, Switzerland) [22]. ROIs
were drawn manually using the whole brain for 18F-FDG
studies and striatum for 18F-fallypride studies. Tracer up-
take was quantified as standardized uptake value (SUV) by
normalizing the average activity concentration (counts per
second per milliliter) of each volume of interest (VOI) to
the injected dose per body weight (MBq/kg).
Measurement of physiological parameters
Body temperature of all animals under isoflurane
anesthesia was monitored using a rectal temperature sen-
sor. A stream of warm air was blown through the scanner
tube to avoid hypothermia during anesthesia and to keep
body temperature constantly between 35°C and 37°C.
Depth of anesthesia monitoring was achieved by sensing
the breath rate with an abdominal breathing belt (rats) or
by visual breath rate counting (mice). The breath rate was
kept constant at a rate of approximately 60 breaths/min
by adjustment of anesthesia.
Assessment of test-retest variability of 18F-FDG whole
brain and 18F-fallypride striatum uptake
Three static PET scanning experiments were performed
for each individual animal of a group to assess the vari-
ability between brain scans of the same animal (intra-ani-
mal variability) and scans of different individuals (inter-
animal variability). Between scans, animals underwent one
week of recovery. 18F-FDG scans were performed with SD
rats (male, 200 to 300 g, n= 6) and 18F-fallypride scans
with NMRI mice (male, 34 to 39 g, n=7) and C57Bl/6 J
mice (male, 18 to 26 g, n= 7). The 18F-FDG study was per-
formed twice using two independent batches of animals,
referred to as study 1 and study 2. Variability of tracer up-
take to the brain (18F-FDG) or striatum (18F-fallypride)
was calculated as coefficient of variation (COV), corre-
sponding to the relative standard deviation of the mean.
Influence of experimental parameters on 18F-FDG and
18F-fallypride biodistribution
To determine the impact of different experimental para-
meters on 18F-FDG biodistribution, animals underwent
PET scanning according to protocols 1 or 2. Subsequent to
PET imaging, animals were euthanized by decapitation at
approximately 61 min p.i. Organs and tissues were col-
lected; the wet weights were determined, and the samples
were measured by classical gamma counting (Wallac 1480
Wizard, PerkinElmer Instruments, Boston, MA, USA).
Radiotracer uptake was expressed as percentage of injecteddose per gram tissue normalized to the body weight of the
animals (normalized percent injected dose per gram
(norm. %ID/g)) and calculated as follows: sample activity
(counts per minute)100/[injected dose (counts per min-
ute)sample weight (grams)]/body weight (kilograms). Indi-
vidual test parameters of experiments are listed in Table 1.
Anesthetic protocols (male SD rats, 220 to 280 g, n = 6)
The impact of anesthetic protocols on 18F-FDG organ
and tissue uptake was investigated by applications of iso-
flurane anesthesia of different durations (0 to 61 min p.i.
for dynamic PET scanning (PET protocol 2), 20 to 61
min p.i. for static PET scanning (PET protocol 2), and 55
to 61 min p.i. as control conditions).
Temperature (male NMRI mice, 18 to 46 g, n = 8)
Animals underwent a static PET scanning protocol (PET
protocol 2). Temperature control during 18F-FDG up-
take phase (0 to 20 min p.i.) was achieved by placing the
animal under an infrared lamp subsequent to tracer in-
jection. The temperature at the position of the animal
was 33°C. Control animals were kept in the same room
at 23°C.
EtOH in the administered tracer solution (18F-FDG: male
NMRI mice, 18 to 46 g, n = 8; 18F-fallypride: male C57Bl/6 J
mice, 20 to 25 g, n = 8)
18F-FDG or 18F-fallypride were injected in physiological
saline solution containing 10% of EtOH (v/v). This
amount corresponds to a blood concentration of ap-
proximately 4% ethanol for a mouse of average size.
Tracer solutions injected to control animals did not con-
tain 10% EtOH. Experimental handling, data collection,
and interpretation were performed in a blinded fashion.
Analysis of homogenization vs. pseudo-heterogenization
Comparison of homogenization with heterogenization of
test groups was performed according to the study of Richter
and co-workers (Figure 1) [7]. 18F-FDG scans according to
PET protocol 1 were performed with eight groups of NMRI
mice under different homogenized conditions. Animals
were sacrificed subsequent to the PET scan (61 min p.i.); 19
organs and tissue samples were collected and measured by
classical gamma counting. The data of all 4 × 8 animals of
each gender were pooled, and the ‘true’ gender differences
in 18F-FDG uptake were determined. Gender differences in
18F-FDG tissue distribution were then assessed by compar-
ing four pairs of highly homogenized test groups (an ex-
ample of one homogenized pair is indicated in dark grey,
Figure 1). Each pair was statistically analyzed using a two-
tailed Student's t test with subsequent Bonferroni correc-
tion. The identified gender differences were compared with
the ones determined in the pooled setup, and the number
of false positive differences was assessed. This step was
Figure 2 Different variability types. (A) Different types of
variability of 18F-FDG brain SUV in male Crl:CD(SD) rats (n= 6). Each
data point corresponds to the 18F-FDG brain SUV of one individual
animal. Intra-animal variability is the variability between three brain
scans of one individual (indicated in red). (B) Column bar
representation of the data from (A). Inter-animal variability is the
variability between brain SUVs of different individuals acquired on
the same test day (represented by the SD, indicated in blue). Inter-
study variability is the variability of 18F-FDG brain SUVs between two
independent test groups acquired under exactly the same
experimental conditions (indicated in green); *P< 0.05.
Figure 1 Experimental design of homogenization vs.
heterogenization. The scheme of the experiment is in analogy to
the study of Richter et al. [7]; 8 × 8 animals underwent 18F-FDG scans
according to PET protocol 1. Varying experimental parameters were
gender, age, and cage occupancy of the animals (n= 2 or n= 13 per
cage). Animal groups were divided according to gender. This setup
allowed for four strictly homogenized test group comparisons with
the only parameter varying being gender (one example of such a
comparison pair is indicated in dark gray). On the other hand, by
reordering the same data into 8 × 8 randomized groups, four
comparisons of such pseudo-heterogenized groups were performed
(indicated by the light grey squares).
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randomly distributing the same data to eight ‘new’ groups
(indicated in light grey, Figure 1). The variability (COV) of
18F-FDG tissue uptake between and within groups (2×4
homogenized groups and 2×4 pseudo-heterogenized
groups) was calculated and compared using a nonpara-
metric Wilcoxon signed rank test. By adapting the signifi-
cance level α for the heterogenized data, the false negative
rate was brought to the same level as the one arising from
the homogenized setup, thereby achieving direct compar-
ability of false positive rates via a t test.
Statistical analysis
Figures show mean±SD, unless stated otherwise. Differ-
ences among experimental groups in SUVs and percent
injected dose per gram values of the various tissues inves-
tigated were statistically evaluated by analysis of variance
(ANOVA) and subsequent post hoc Tukey tests for com-
parisons of three or more groups and by two-tailed Stu-
dent's t tests of unpaired samples for comparisons of two
groups. Intraindividual variability COVs were statistically
compared using a paired sample Student's t test. Statisticalsignificance was set at the 95% level, and Bonferroni cor-
rection was applied where required. All statistical analyses
were performed using the computer software SPSS 15.0
version for Windows (SPSS Inc. Chicago, Illinois).
Results and discussion
Results
Test-retest variability of 18F-FDG brain uptake and striatal
uptake of 18F-fallypride
The different variability types investigated are illustrated in
Figure 2A. Inter- and intra-animal variability of 18F-FDG
brain uptake did not differ significantly: 8 ± 2% (inter-ani-
mal COV) compared to 10±4% (intra-animal COV) for
the first study, and 14±7% (inter-animal COV) compared
to 21±10% (intra-animal COV) for the second study. By
trend, intra-animal variability was greater than inter-animal
variability. Repetition of the test-retest setup resulted in an
inter-study variability of 10±6% for 18F-FDG brain uptake.
18F-FDG brain uptake of retest 1 compared to either test
or retest 2 proved to be significantly different (16% and
24%, P< 0.05; Figure 2B).
Figure 3 18F-fallypride SUV in striatum, retina, and cerebellum. Black, striatum; red, retina; blue, cerebellum. NMRI mice (light colors): n= 6,
C57Bl/6 J mice (dark colors): n= 7; ***P< 0.001.
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atum uptake did not differ significantly: 16±4% (inter-ani-
mal COV) compared to 23±8% (intra-animal COV) for
C57Bl/6 J mice, and 11±4% (inter-animal COV) compared
to 9±8% (intra-animal COV) for NMRI mice. Likewise,
18F-fallypride striatum uptake between individual test days
did not differ significantly, whereas NMRI mice tended
to accumulate more 18F-fallypride in the striatum than
C57Bl/6 J mice; on the third test day, the difference was sig-
nificant (Figure 3). Strain differences also occurred concern-
ing accumulation of 18F-fallypride in the eye region. The
very high 18F-fallypride accumulation in the eye region
observed in C57Bl/6 J mice was mainly due to a non-block-
able uptake or binding to the retina (autoradiography
experiments, unpublished results). This phenomenon was
not observed in NMRI mice; 18F-fallypride accumulation in
the eye region was in the background range, comparable
with cerebellum uptake (Figure 3).
Impact of experimental parameters on 18F-FDG and
18F-fallypride ex vivo tissue distribution
The anesthetic protocol (PET protocol 1 vs. 2) had a
significant impact on 18F-FDG uptake in several tissues.
18F-FDG brain uptake of animals anesthetized during the
whole tracer uptake phase (protocol 2) was reduced by 27%
compared to animals investigated under protocol 1 condi-
tions (P< 0.01). Protocol 1 resulted in a 17% reduction of
brain uptake compared with the control group which was
not scanned (short anesthesia of 6 min for humane decapi-
tation; P< 0.01). 18F-FDG muscle uptake showed a similar
pattern as brain uptake with highest uptake under control
conditions (P< 0.01). Contrary to these findings, 18F-FDG
blood concentration was lowest in the control and high-
est in the test group investigated according to protocol
2 (P< 0.01), as shown in part A of Table 2. An ambienttemperature of 33°C during the first 20 min after 18F-FDG
injection resulted in 40% decreased 18F-FDG brown fat tis-
sue uptake compared with control animals at room
temperature (r.t.) or animals with 10% ethanol co-admin-
istration at r.t. (not significant). Ethanol seemed to coun-
teract the reduced 18F-FDG brown fat tissue uptake
observed at 33°C ambient temperature alone. Further-
more, animals receiving 10% ethanol showed a 34% de-
crease in muscle uptake compared with the test group
kept at higher ambient temperature (P< 0.05, part B of
Table 2). Ex vivo biodistribution of 18F-fallypride was not
significantly influenced by 10% ethanol in the adminis-
tered tracer solution. Nevertheless, there was a trend to-
wards increased 18F-fallypride accumulation in the
striatum under ethanol conditions (16%, not significant,
part C of Table 2). Gender and age of test animals proved
to significantly impact 18F-FDG uptake to certain periph-
eral organs, but not to the brain. More than double the
amount of 18F-FDG was accumulated in the fat of
females compared with males (P< 0.01), whereas
18F-FDG blood concentration was 33% higher in males
(P< 0.01, part D of Table 2). Older animals accumulated
13% less 18F-FDG in their bone marrow (P< 0.05) and
28% more 18F-FDG in their Harderian glands (P< 0.01)
compared with the younger mice. The potential influence
of combined effects of two or three of the investigated
parameters was excluded by performance of a three-way
ANOVA where no significant differences due to multiple
parameters were confirmed.
Homogenization vs. pseudo-heterogenization
In analogy to the study of Richter and co-workers [7], it
was investigated whether strict homogenization of experi-
mental test groups in small animal 18F-FDG PET might
lead to reduced reproducibility of results compared with
Table 2 Influence of experimental parameters on tissue distribution of 18F-FDG or 18F-fallypride expressed as normal
%ID/g (mean± SD)
Part Experimental parameter Organ
A Anesthetic protocol (18F-FDG) Brain Muscle Blood
Control 0.31 ± 0.04 0.066 ± 0.026 0.015 ± 0.006
Dynamic 0.19 ± 0.04** 0.028 ± 0.006** 0.051 ± 0.009**
Static 0.26 ± 0.02** 0.04 ± 0.006** 0.033 ± 0.004**
B Ambient temperature/10% EtOH (18F-FDG) Brown fat tissue Muscle
r.t. (23°C) 0.30 ± 0.18 0.097 ± 0.038
33°C 0.18 ± 0.07 (n.s.) 0.119±0.016*
r.t./10% EtOH 0.37 ± 0.14 0.08±0.023*
33°C/10% EtOH 0.40 ± 0.19 0.089 ± 0.018
C 10% EtOH (18F-fallypride) Striatum
r.t. (23°C) 0.25 ± 0.03 (n.s.)
33°C -
r.t./10% EtOH 0.28 ± 0.03 (n.s.)
33°C/10% EtOH -
D Gender (18F-FDG) Liver Blood Fat Reproductive organs
Female 0.018 ± 0.005 0.01 ± 0.003 0.024 ± 0.015 0.052± 0.017
Male 0.022 ± 0.006* 0.015 ± 0.005** 0.011 ± 0.009** 0.041± 0.009**
E Age (18F-FDG) Bone Harderian gland Urine
5 weeks 0.097 ± 0.016 0.45 ± 0.12 3.4 ± 2.3
14 weeks 0.084 ± 0.022* 0.63 ± 0.22** 1.9 ± 1.1*
n.s., Not significant. Part A is the influence of anesthesia duration on 18F-FDG distribution. **P< 0.01 for comparison with control condition. Ex vivo biodistribution
of 18F-FDG in Crl:CD(SD) rats (male), n= 6. Control: anesthesia from 55 to 61 min p.i.; dynamic: anesthesia from 0 to 61 min p.i.; static: anesthesia from 20 to 61
min p.i. Part B is the influence of ambient temperature and ethanol application on 18F-FDG distribution. *P< 0.05 for comparison between conditions in bold. Ex
vivo biodistribution of 18F-FDG in NMRI mice (male) under control conditions, ambient temperature control between 0 to 20 min p.i., 10% ethanol in the
administered tracer solution (10 μL ethanol) and a combination of the two; n= 8. Part C is the influence of ethanol in the tracer solution on 18F-fallypride
distribution. Ex vivo biodistribution of 18F-fallypride in C57Bl/6 J mice (male), n= 8. Comparison of mice receiving 10% ethanol in the administered tracer solution
(corresponding to 10 μL ethanol) with control animals. Part D is the influence of gender, age, and cage occupancy on 18F-FDG biodistribution. *P< 0.05,
**P< 0.01. ex vivo biodistribution of 18F-FDG in male and female NMRI mice (n= 38 for males, n= 44 for females). Part E is the ex vivo biodistribution of 18F-FDG in
14 weeks and 5 weeks old NMRI mice (n= 40 for ‘old’ animals and n= 42 for ‘young’ animals). *P< 0.05, **P< 0.01 for comparison between male and female or 5
and 14 weeks old animals, respectively.
Table 3 Influence of homogenization and





Inter-group 32± 2% 28± 2%*
Intra-group 31± 1% 35± 1%**
*P< 0.05, **P< 0.01. Inter- and intra-group variability of 18F-FDG uptake for all
organs measured (mean of COVs ± SEM of homogenized groups vs.
heterogenized groups, in percent).
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genized to the parameters: gender, age, and cage occupancy
(Figure 1). Therefore, 18F-FDG tissue uptake was deter-
mined in eight test groups. In the first step, animals with
the same gender were pooled into one group of 4× 8 ani-
mals in order to determine true gender differences in
18F-FDG tissue uptake. Such true differences were found
for 2 tissues (blood and fat) out of 19 (2 positive findings
vs. 17 negative ones). Having assessed the true positives,
gender differences of 18F-FDG uptake in 19 different
organs and tissue samples were determined by comparing
pairs of groups only differing in gender. Inter- and intra-
group variability (COV) of 18F-FDG tissue uptake was
determined and compared with the results from the
pseudo-heterogenized setup (Figure 1). The intra-group
18F-FDG tissue uptake COVs were 17% greater for the het-
erogenized groups compared with those of the homoge-
nized groups (P< 0.01). On the other hand, the variabilitybetween different test groups was 13% smaller for the het-
erogenized setup (P< 0.05) as shown in Table 3.
The false positive rate of homogenized and pseudo-
heterogenized results was determined by comparison with
true gender differences of 18F-FDG tissue uptake that
resulted to pooled data of the same gender. It was investi-
gated whether strict homogenization leads to increased
false positive rates of results. Homogenized test groups
Table 4 Comparison of false positive and false negative










False positive rate (%) 9 ± 5 2 ± 3 6 ± 6
False negative rate (%) 63 100* 63
*P< 0.05. For heterogenized groups, α was adapted from 0.05 to 0.38 in order
to achieve the same study power as in the homogenized setup; n= 4; mean of
false positive/negative rates ± SEM in percent.
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whereas heterogenized test groups resulted in 2±3% false
positives (not significant, Table 4). The two false positive
rates determined at a significance level α of 5% cannot be
compared with each other directly due to power differ-
ences. The power and the significance level α of a study are
dependent on each other (i.e., if alpha increases, the power
increases as well). In addition to that, study power increases
with increasing homogenization as homogenization
reduces variability of data. Therefore, the false negative rate
of the two setups needed to be compared as well (study
power=1− false negative rate). The false negative rate of
the homogenized setup was significantly lower than one of
the heterogenized study (63% vs. 100%, P< 0.05; Table 4).
The significance level α of the pseudo-heterogenized setup
was therefore adapted from 0.05 to 0.38 in order to achieve
a comparable study power for both setups (power 37%).
The recalculated (using the adapted α) false positive rate of
heterogenized samples was 6±6% compared to 9±5% for
the homogenized ones (not significant, Table 4).
Discussion
For 18F-FDG experiments, the brain was chosen as the
main organ of interest as it was assumed that it is a well
identifiable organ in small animal PET scans with reason-
ably low inherent variability of metabolism between indi-
vidual animals. It is important to bear in mind that the
resulting data is not valid for other tissues or organs of the
mouse or rat body to the same extent. Nevertheless, it
might be reasonable to assume that the inherent tracer up-
take variability to different organs or tissue would either be
in a similar range or even higher. The reproducibility of
18F-FDG rat brain PET scans was not found to be
improved by repeated measurement of the same animal.
The variability of 18F-FDG brain uptake and of striatal
18F-fallypride accumulation between scans of the same ani-
mal (intra-animal variability) compared with scans of dif-
ferent individuals (inter-animal variability) was higher by
trend (not significant). Furthermore, measuring the same
group of animals repeatedly produced significantly differ-
ent brain SUVs on different test days. This might be due to
the fact that these animals have already experienced radio-
tracer injection, anesthesia, and general experimentalhandling, which might impact the metabolism of individual
animals, e.g., the variability in body temperature during the
PET scan. Body temperature of animals under anesthesia
was maintained between 35°C and 37°C. This temperature
variation was in a similar range as reported by Fueger et al.
[11]. In addition, animals were one week older at the time
point of the retest. The most plausible explanation, how-
ever, would be that the determined significances are false
positives as it is known that strict standardization leads to a
clear increase of the false positive rate [7]. It is therefore ad-
visable to use heterogenized experimental conditions in
order to avoid high false positive rates. Controlling hetero-
genized conditions is very important as certain parameters
might crucially impact study outcome, and such parameters
should be standardized to reach a satisfactory study power.
Several parameters with a potential impact on 18F-FDG
biodistribution were investigated in detail. Of all tested
parameters, anesthetic protocols proved to influence
18F-FDG brain uptake the most. Therefore, it is suggested
to standardize anesthetic protocols to produce reliable
small animal 18F-FDG brain PET data. Results revealed
that duration of wakefulness during the first phase of tracer
uptake was directly related to 18F-FDG brain uptake, which
is presumably due to a decreased cerebral metabolic glu-
cose rate under isoflurane anesthesia [23]. These results
confirm similar findings of the impact of isoflurane on
18F-FDG brain uptake [11,12,14]. 18F-FDG muscle uptake
showed a similar decrease with anesthesia duration. This ef-
fect is most probably due to the lack of motion during
anesthesia. On the other hand, blood content of 18F-FDG
was clearly higher, the longer the duration of anesthesia; this
effect might arise from reduced elimination of 18F-FDG.
Experimental parameters such as ambient temperature,
gender, and age significantly altered 18F-FDG uptake to
liver, fat tissue, Harderian glands, and bone marrow. The
reduced brown fat tissue uptake of 18F-FDG at an increased
ambient temperature is in line with the findings of Fueger
and co-workers [11]. In this study, mice were kept at ambi-
ent temperatures of thermoneutrality, which is between 30°
C and 34°C for mice. In the thermoneutrality zone, brown
fat dependent thermoregulation does not take place. While
it is obvious that increased ambient temperature during
18F-FDG uptake leads to a decreased brown fat uptake
compared with animals kept at room temperature, the im-
pact of age on bone marrow and Harderian gland uptake is
less apparent. It seems that young animals might have an
increased glucose turnover rate in bone marrow. 18F-FDG
fat tissue uptake was higher in females compared with that
in males, which might be explained by a higher generation
of fat deposits in females. An ethanol concentration of 10%
in the tracer solution did generally not impact 18F-FDG or
18F-fallypride tissue distribution significantly, but the
reduced 18F-FDG brown fat uptake at 33°C ambient
temperature was counteracted by ethanol in the tracer
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[24], which might be compensated by glucose metabolism
within the brown fat tissue. Additionally, 18F-fallypride stri-
atum uptake was increased in animals receiving ethanol
compared with that in control animals (16%, not signifi-
cant). This trend supports the hypothesis that the rate of
metabolic transformation of 18F-fallypride might be slowed
down under acute ethanol conditions. It was assumed that
18F-fallypride is metabolized via an oxidative process in the
liver. Acute ethanol administration is known to induce hyp-
oxia in the liver [25] and is therefore believed to impact the
enzyme capacity of oxygenating enzymes. Ethanol was
therefore expected to slow down the degradation process
of 18F-fallypride, a low extraction compound, resulting in
altered uptake characteristics in its target organs (mainly
the striatum). Varying contents of ethanol in the 18F-fally-
pride solution might therefore lead to increased inter-ani-
mal variability of striatum uptake, which may be
considered for an optimal tracer formulation in future
experiments.
It was previously reported that overnight fasting was
beneficial for small animal 18F-FDG study outcome due
to reduced competition of glucose with 18F-FDG for cel-
lular uptake [11,16,26,27]. For this study, it was assumed
that fasting of animals might conduce positively to the
experimental outcome in two ways. Besides increasing
the overall organ uptake of 18F-FDG, it was expected
that the variability of blood glucose levels of individual
animals would be reduced crucially and a relatively uni-
form low glucose concentration would be reached. This
was assumed to reduce the inter-animal variability of
18F-FDG tissue uptake. However, a pilot experiment
showed that fasting did not lead to reduced blood glu-
cose levels or reduced variability of blood glucose con-
centration (data not shown). One reason for this might
be the short fasting duration of only 4 h that was used
to fulfill the regulations of the local authorities. These
findings superseded a dedicated experiment to study the
influence of blood glucose levels on 18F-FDG tissue up-
take. Fasting of animals prior to 18F-FDG was therefore
omitted in this study.
The homogenization study according to a protocol by
Richter and co-workers [7] suggests that a low intra-group
variability does not necessarily correspond to low inter-
group variability as generally assumed [5,6]. The signifi-
cantly higher false positive rate under homogenized
conditions reported by Richter and colleagues were not
confirmed, most probably due to the smaller scale of this
study (4 group comparisons per homogenized and hetero-
genized setup in this study vs. 18 group comparisons per
setup in the study of Richter and co-workers). Nonetheless,
the results revealed a clear trend towards affirmation of the
findings by Richter et al. [7]. Regarding the low power of
this study as well as the fact that the setup mixed empiricalwith data-mining data, it is important to interpret our
results with care. Mainly, the results indicate that
homogenization of experimental setup might not only be a
problem in behavioral studies, but also in molecular im-
aging. This prompts more research in this regard as well as
underlines the importance of careful interpretation and ex-
trapolation of research results to the clinic. In the future,
it might be worthwhile to investigate this topic by includ-
ing different research centers to generate experimental
heterogenization.
This study also shows that the variability of 18F-FDG
tissue uptake is strongly dependent on the tissue of
interest. Brain uptake was rather stable with a variability
ranging from 6% to 16%, whereas the variability of 18F-
FDG concentrations in blood and the Harderian gland
was in a range of 20% to 40%. Considering this high
variability for 18F-FDG organ uptake, it is advisable to
perform sample size calculations prior to experiments to
avoid exclusion of effects due to unsatisfactory study
power. Furthermore, it shows the range of effect size
that can still be detected with small animal PET without
being lost in evitable variability.
Conclusions
Small animal PET studies should be designed with care,
taking into account that using animals as their own con-
trol does not necessarily increase reliability of results. Fur-
thermore, experimental parameters which do not impair
tracer distribution significantly (e.g., ambient temperature,
housing conditions, gender, and age of animals) are sug-
gested to be varied in a controlled manner to produce
results with maximal external validity. In the future, it
would be worthwhile to perform studies involving differ-
ent PET centers pursuing small animal imaging to investi-
gate closer the external validity of the results.
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